Neuroprotective effects of Neurotrophin-3 in MPTP-induced zebrafish Parkinson’s disease model

Abstract

Introduction: Neurotrophin-3 (NT3) is a neuroprotective growth factor that induces the development, maintenance and survival of neurons. This study aims to localize NT3-expressing cells in the adult zebrafish brain and examine the role of NT3 in a zebrafish Parkinson’s disease (PD) model.Methods: Cellular localization of NT3 in adult zebrafish brains was conducted using in situ hybridization. Subsequently, adult zebrafish were injected intraperitoneally with 100 μg/g of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and treated with 400 ng/g body weight of recombinant NT3 (rNT3) via intracranial injection 24 h following MPTP injection. The fish were assessed for neurobehavioral, gene expression, immunohistology, and protein analysis on days 3, 5 and 10 post-MPTP injection.Results: Our findings showed that NT3 was extensively expressed throughout the adult zebrafish brain in neurons. Administration of rNT3 has significantly improved locomotor activity, with upregulation of th1, dat, ntf3 and bdnf gene expressions compared to MPTP-induced zebrafish. Dopaminergic neurons were also significantly increased in the zebrafish brain following rNT3 treatment. ELISA analysis reported raised GST and decreased caspase-3 levels on day 3 of assessment. The trophic changes of rNT3, however, decline as the assessment day progresses.Conclusion: This study is the first to examine the role of NT3 in the adult zebrafish PD model. NT3 has remarkable trophic effects in the zebrafish PD model. However, further study is needed to examine the dosage requirements and long-term effects of NT3 in PD.

Identification of key genes and signaling pathway in the pathogenesis of Huntington's disease via bioinformatics and next generation sequencing data analysis

“…CD74 [493], VWF (von Willebrand factor) [267], MTTP (microsomal triglyceride transfer protein) [494], ANGPT2 [184], AKR1C3 [495], NEDD4L [496], CASP1 [497], LDB2 [498], CHRNA5 [499], CCND2 [500], BRCA2 [97], ZBTB20 [501], EFNB2 [502], CYP7B1 [503], DCLK1 [504], RBM20 [505], PLCE1 [197], EGFR (epidermal growth factor receptor) [276], ABCA1 [506], PDPN (podoplanin) [507], SCN4B [508], SLCO1B1 [509], CRHR2 [510], RND3 [511], COMT (catechol-O-methyltransferase) [512], GPR39 [513], GRB14 [514], HDC (histidine decarboxylase) [515], DAPK2 [516], SMAD9 [517], TXNRD2 [518] and KIF15 [519] are altered expressed in cardiovascular diseases. Previous studies have proven that the FGF8 [520], SERPINA1 [521], LRRK2 [522], CHRNA4 [523], TF (transferrin) [524], TRDN (triadin) [525], NR0B1 [526], RELN (reelin) [527], HTR2C [528], RIT2 [529], REN (renin) [530], TLR2 [531], MOBP (myelin associated oligodendrocyte basic protein) [532], TNR (tenascin R) [533], ADGRB1 [534], GPR37 [535], SHH (sonic hedgehog signaling molecule) [536], XDH (xanthine dehydrogenase) [537], SIRT2 [538], BMP2 [539], HAS2 [540], CSMD1 [541], NTF3 [542], SNCB (synuclein beta) [543], MMP3 [544], HLA-DRB5 [545], HLA-DRB1 [546], HLA-DRA [547], VWF (von Willebrand factor) [548], AKR1C3 [549], CASP1 [550], CHRNA5 [551], TET1 [552], LRRN3 [553], EGFR (epidermal growth factor receptor) [554], PLXNA4 [555], FOXG1 [556], MAP1B [557], ANK1 […”